Skip to main content

Table 3 Success rates of the two groups

From: Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma

 

2 weeks

1 month

3 months

6 months

12 months

Injection Group

95.2 %

90.5 %

80.0 %

73.7 %

72.2 %

(Successful subjects/total subjects)

(20/21)

(19/21)

(16/20)

(14/19)

(13/18)

Control Group

90.9 %

81.8 %

77.3 %

71.4 %

68.4 %

(Successful subjects/total subjects)

(20/22)

(18/22)

(17/22)

(15/21)

(13/19)

P

0.57

0.41

0.83

0.87

1.00

  1. Note: Success was defined as IOP > = 6 mm Hg and < = 21 mm Hg, with or without the use of anti-glaucoma medications, and without severe complications or reoperation. The differences in the success rates were compared between the two groups using the corrected chi-square test (two weeks, one month, and three months) and chi-square test (six months) and two-tailed Fisher’s exact test (12 months)